Werewolf Therapeutics, Inc.

HOWL

US95075A1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-05 EDT			5-day change	1st Jan Change
2.08 ^USD	-2.80%		-14.75%	-46.11%

07-01	Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell Small Cap Comp Value Index	CI
07-01	Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell Small Cap Completeness Index	CI

Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell Small Cap Comp Growth Index

July 30, 2024

Latest news about Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell Small Cap Comp Value Index	06-30	CI
Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell Small Cap Completeness Index	06-30	CI
Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell Microcap Growth Index	06-30	CI
Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell 3000 Value Index	06-30	CI
Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell 2000 Index	06-30	CI
Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell 3000E Index	06-30	CI
Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell 2500 Value Index	06-30	CI
Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell 3000E Growth Index	06-30	CI
Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell 3000 Growth Index	06-30	CI
Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell 2000 Value Index	06-30	CI
Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell 2000 Growth Index	06-30	CI
Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell 2000 Dynamic Index	06-30	CI
Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell 2500 Growth Index	06-30	CI
Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell Small Cap Comp Growth Index	06-30	CI
Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell 2500 Index	06-30	CI
Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell 3000 Index	06-30	CI
Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) added to Russell 3000E Value Index	06-30	CI
Werewolf Therapeutics Says Initial Data Show Potential Non-Hodgkin Lymphoma Treatment Increased Therapeutic Window in Phase 1 Clinical Trial	06-25	MT
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma	06-25	CI
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1B Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors	06-01	CI
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting	05-23	CI
Werewolf Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-03	CI
Werewolf Therapeutics, Inc. Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease at AAI Annual Meeting	04-23	CI
Werewolf Therapeutics, Inc. Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics	04-05	CI
JMP Securities Starts Werewolf Therapeutics With Market Outperform Rating, $12 Price Target	04-03	MT

Chart Werewolf Therapeutics, Inc.

Duration

Period

More charts

Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the bodyâs immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Werewolf Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.08 USD

Average target price

12.5 USD

Spread / Average Target

+500.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
WEREWOLF THERAPEUTICS, INC.	-46.11%	90.39M
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research